Streptococcus Pneumoniae Infection

AMXT-1501 tetrahydrochloride is a Bacterial agent and polyamine transport system inhibitor. AMXT-1501 tetrahydrochloride targets membrane phospholipids and exhibits antibacterial activity against a variety of Gram-positive and Gram-negative multidrug-resistant bacteria. AMXT-1501 tetrahydrochloride inhibits capsular biosynthesis in Streptococcus pneumoniae. AMXT-1501 tetrahydrochloride targets ornithine decarboxylase and polyamines to inhibit the proliferation of neuroblastoma cells. AMXT-1501 tetrahydrochloride in combination with DFMO (HY-B0744) induces Apoptosis in neuroblastoma cells. AMXT-1501 tetrahydrochloride is applicable to research related to multidrug-resistant bacterial infections, pneumococcal infections, Streptococcus pneumoniae infections, and neuroblastoma.

AMXT-1501 is a Bacterial agent and polyamine transport system inhibitor. AMXT-1501 targets membrane phospholipids and exhibits antibacterial activity against a variety of Gram-positive and Gram-negative multidrug-resistant bacteria. AMXT-1501 inhibits capsular biosynthesis in Streptococcus pneumoniae. AMXT-1501 targets ornithine decarboxylase and polyamines to inhibit the proliferation of neuroblastoma cells. AMXT-1501 in combination with DFMO (HY-B0744) induces Apoptosis in neuroblastoma cells. AMXT-1501 is applicable to research related to multidrug-resistant bacterial infections, pneumococcal infections, Streptococcus pneumoniae infections, and neuroblastoma.

Ceftaroline (T-91825) is a cephalosporin compound and the active form of Ceftaroline fosamil (HY-14737). Ceftaroline exhibits activity against Gram-positive bacteria, Gram-negative bacteria, and some anaerobic bacteria. Ceftaroline binds to penicillin-binding proteins 2 and 2A, thereby inhibiting the synthesis of bacterial peptidoglycan and cell wall, and acts as a bactericide, synergist, and resistance inhibitor. Ceftaroline can be used in research related to complicated skin and soft tissue infections, community-acquired pneumonia, Enterococcus faecalis infective endocarditis, and bacterial infections.

Rhodionin is an orally active, multifunctional antivirulence and cytoprotective agent that targets and inhibits Lipase, sortase A (SrtA), CYP2D6 (IC₅₀=0.761 μM), AChE (IC₅₀=2.43-57.5 μM), and DPPH free radicals (IC₅₀=19.49 μM). Rhodionin is isolable from the roots of Rhodiola crenulata. Rhodionin reduces postprandial serum triglyceride levels in mice by inhibiting lipase activity. Rhodionin also binds directly to SrtA to inhibit its transpeptidase activity, thereby reducing the fibrinogen adhesion and surface protein A levels of MRSA, effectively inhibiting biofilm formation and protecting against MRSA-induced cell damage. Rhodionin improves the survival rate of infected mice without affecting MRSA growth, and finds wide application in studies related to hyperlipidemia, exogenous obesity, and pneumonia induced by methicillin-resistant Staphylococcus aureus (MRSA).

Anti-Mouse CD209b Antibody (22D1) is an anti-mouse CD209b IgG1 antibody inhibitor derived from the host Armenian Hamster. Anti-Mouse CD209b Antibody (22D1) can block SIGN-R1. Anti-Mouse CD209b Antibody (22D1) can be used for the researches of infection, inflammation and immunology, such as toxoplasma infection and pneumonia.

Antimicrobial peptide 6b is a cationic macrocyclic antimicrobial peptide. It exhibits broad-spectrum antibacterial and antifungal activities, with a MIC of 1.5-6.2 μg/mL against drug-resistant Gram-positive bacteria, a MIC of 4-25 μg/mL against Gram-negative bacteria, and also shows activity against pathogenic fungi. It acts through a membrane disruption mechanism, has a unique "sandwich" conformation, low hemolytic activity, and can rapidly kill bacteria and eliminate bacterial and fungal biofilms. Antimicrobial peptide 6b can be used in studies of drug-resistant bacterial infections and fungal infections.

DK 507k is an orally active 8-methoxyquinolone Antibacterial agent. DK 507k targets DNA gyrase subunit A (GyrA) and modulates the function of GyrA. DK 507k inhibits the growth of various Gram-positive and Gram-negative bacteria, including Pseudomonas aeruginosa and Methicillin (HY-121544)-resistant Staphylococcus aureus. DK 507k eliminates Penicillin-tolerant Streptococcus pneumoniae from the lungs of mice. DK 507k can be used in research related to sepsis and *Streptococcus pneumoniae* pneumonia.

ZLWH-67 is a β-Carboline derivative and Antibacterial agent. ZLWH-67 inhibits DNA synthesis, suppresses biofilm formation, and increases reactive oxygen species (ROS) levels. ZLWH-67 exhibits potent in vitro antibacterial activity against MRSA (MIC = 0.5-4 μg/mL), S. epidermidis (MIC = 4 μg/mL), E. faecalis (MIC = 4-8 μg/mL), and S. pneumoniae (MIC = 16 μg/mL). ZLWH-67 displays anti-MRSA effects in murine skin and pneumonia infection models.

Ceftaroline hydrochloride is a cephalosporin compound and the active form of Ceftaroline fosamil (HY-14737). Ceftaroline hydrochloride exhibits activity against Gram-positive bacteria, Gram-negative bacteria, and some anaerobic bacteria. Ceftaroline hydrochloride binds to penicillin-binding proteins 2 and 2A, thereby inhibiting the synthesis of bacterial peptidoglycan and cell wall, and acts as a bactericide, synergist, and resistance inhibitor. Ceftaroline hydrochloride can be used in research related to complicated skin and soft tissue infections, community-acquired pneumonia, Enterococcus faecalis infective endocarditis, and bacterial infections.

WK2 is an antibacterial agent. WK2 reduces serum TNF-α production induced by Bacterial infection. WK2 reduces wound size and promotes tissue repair in a skin wound infection model. WK2 exerts anti-inflammatory effects in a pneumonia model. WK2 can be used for research on infectious diseases such as pneumonia caused by bacterial infection.

Chinenol A is an antibacterial agent that can be found in the aerial part of Helwingia chinensis. Chinenol A can be used for the research of bacterial infections (staphylococcus aureus infection, mycobacterium tuberculosis infection, streptococcus pneumonia infection).

Nafithromycin (WCK 4873) is an orally active ketolide antibiotic with activity against Gram-positive bacteria, Gram-negative bacteria, and atypical respiratory pathogens (including drug-resistant strains). Nafithromycin binds to domains II and V of bacterial 23S rRNA and the peptidyl transferase center of the 50S ribosomal subunit, thereby inhibiting protein synthesis. Nafithromycin can be used in research related to bacterial infections.

LB 11058 is a Cephalosporin Antibacterial agent. LB 11058 inhibits the growth of pathogenic bacteria, including multidrug-resistant staphylococci and streptococci, but shows weak activity against Enterococcus faecium, Corynebacterium species, Enterobacteriaceae and non-fermenting Gram-negative bacilli. LB 11058 can be used in bacterial infection research.

Azithromycin-amide-C3-amide-quinoxaline (Compound 5f) is an Azithromycin (HY-17506) derivative and antibacterial agent. Azithromycin-amide-C3-amide-quinoxaline inhibits topoisoisomerase I with an IC₅₀ of 120.7 μM. Azithromycin-amide-C3-amide-quinoxaline interacts with 70S E. coli ribosome with a K_d of 0.8 nM. Azithromycin-amide-C3-amide-quinoxaline inhibits bacterial translation with an IC₅₀ of 0.7 μM. Azithromycin-amide-C3-amide-quinoxaline shows antibacterial potency against S. pneumonia ATCC 49619, S. aureus ATCC 29213, E. faecalis ATCC 29212 with MICs of 0.06 μg/mL, 2 μg/mL, 0.5 μg/mL, respectively. Azithromycin-amide-C3-amide-quinoxaline exhibits anticancer activity against prostate cancer, colon cancer.

Desmycosin is a macrolide antibiotic. Desmycosin exhibits biological activity against H. influenzae, S.aureus, S. pneumoniae, and S. pyogenes with MIC values of 4, 1, <0.125, and <0.125 µg/ml, respectively. Desmycosin is an acidic degradation product of tylosin.